ASO AUTHOR REFLECTIONS



ASO Author Reflections: Smoking Status Impact on Perioperative Morbidity and Long-Term Survival of Patients Undergoing Esophagectomy for Cancer

Sivesh K. Kamarajah, BMedSci, MBChB¹, and Alexander W. Phillips, MD, MA, FRCSEd^{1,2}

¹Northern Oesophagogastric Unit, Royal Victoria Infirmary, Newcastle University Trust Hospitals, Newcastle-Upon-Tyne, UK; ²School of Medical Education, Newcastle University, Newcastle-Upon-Tyne, UK

PAST

Smoking is established as a risk factor for developing both esophageal adenocarcinoma and squamous cell carcinoma.¹ In addition, it is known to increase perioperative risk. Esophagectomy is associated with high levels of morbidity, and smoking is known to increase these risks.² However, it is not clear what impact smoking status, with regards to being either a current, ex-, and non-smoker, has on perioperative outcomes and long-term survival.

PRESENT

The present study highlights the very real risk that smoking presents for patients undergoing esophagectomy for cancer.³ Complications were higher (73% for smokers versus 62% for non-smokers), as was critical care stay (3 days versus 2 days). This translates to additional costs to healthcare providers. Most importantly, this paper shows the impact on overall survival, with current smokers having median survival of 36 months compared with 48 months

for those who have never smoked, although patients who smoked and received neoadjuvant treatment did not have reduced overall survival.

FUTURE

How smoking affects long-term survival in esophageal cancer patients is still not fully understood. Perhaps the most important question that remains is whether there is a significant benefit for those who smoke at time of diagnosis but then stop at this point. There is an indication that exsmokers do better than those who continue to smoke, but the data on timing of stopping smoking and how this influences prognosis require further study. There may be further genetic profiling that can help identify patients in whom smoking is more detrimental or negates neoadjuvant benefit.

[©] The Author(s) 2021

First Received: 8 February 2021 Accepted: 9 February 2021; Published Online: 5 March 2021

A. W. Phillips, MD, MA, FRCSEd e-mail: awphillips@doctors.net.uk

org/licenses/by/4.0/.

DISCLOSURE The authors declare no conflicts of interest.

OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.

REFERENCES

- Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. *Lancet*. 2017;390(10110):2383–96. https://doi.org/10.101 6/S0140-6736(17)31462-9.
- Griffin SM, Jones R, Kamarajah SK, Navidi M, Wahed S, Immanuel A, Hayes N, Phillips AW. Evolution of esophagectomy for cancer over 30 years: changes in presentation, management and outcomes. *Ann Surg Oncol.* 2020. https://doi.org/10.1245/s10434-020-09200-3.
- Kamarajah SK, Madhavan A, Chmelo J, Navidi M, Wahed S, Immanuel A, et al. Impact of smoking status on perioperative morbidity, mortality, and long-term survival following transthoracic esophagectomy for esophageal cancer. *Ann Surg Oncol.* 2021. https://doi.org/10.1245/s10434-021-09720-6.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.